PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07484269
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Metastatic Prostate Cancer

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer

Key Dates

First listed
Mar 20, 2026
Start date
Aug 1, 2026
Status verified
Mar 2026
Primary completion
Jul 31, 2031
Completion
Jul 31, 2031

Study Design

Enrollment
753 participants (estimated)

Arms

  • Arm: lutetium (177Lu) vipivotide tetraxetan
    Patients with metastatic prostate cancer who are treated with lutetium (177Lu) vipivotide tetraxetan over a five-year followup period

Primary Outcome Measure

Proportion and number of patients who receive any given number of lutetium (177Lu) vipivotide tetraxetan cycles [ Time Frame: From the date of the first administration of lutetium (177Lu) vipivotide tetraxetan (index date) until the end of follow-up, up to 5 years ]

Central Contacts

Related Studies